Fig. 2.

Time-to-recovery analysis for MECs in patients receiving belamaf (2.5 mg/kg) in DREAMM-2. EoT end of treatment, MEC microcyst-like epithelial changes. EoT defined as the last dose date (for patients with an unresolved event at treatment discontinuation) or the event onset date (for patients with an event that started post treatment discontinuation due to any reason). Analysis included patients who were not recovered at EoT exposure (defined as 20 days after the last infusion) and those who had events that started after treatment discontinuation (n = 39). Twenty-one percent (8/39) of patients died before recovery